NeuroMetrix
Medical device company focused on the diagnosis and treatment of the neurological complications of diabetes.
Launch date
Employees
Market cap
CAD11.2m
Enterprise valuation
(CAD11m) (Public information from Sep 2024)
Share price
$3.81 NURO
Waltham Massachusetts (HQ)
Financials
Estimates*
USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 17.1m | 16.1m | 9.3m | 7.4m | 8.3m | 8.3m | 5.9m |
% growth | - | (6 %) | (42 %) | (20 %) | 12 % | - | (29 %) |
EBITDA | (12.8m) | (12.1m) | (11.5m) | (2.1m) | (2.3m) | (4.7m) | (7.1m) |
% EBITDA margin | (75 %) | (75 %) | (124 %) | (28 %) | (28 %) | (57 %) | (120 %) |
Profit | (12.9m) | <1m | (3.8m) | (2.1m) | (2.3m) | (4.4m) | (6.5m) |
% profit margin | (75 %) | - | (41 %) | (28 %) | (28 %) | (53 %) | (111 %) |
EV / revenue | - | -0.1x | 0.3x | 1.1x | 1.4x | -1.1x | -2.4x |
EV / EBITDA | - | 0.1x | -0.2x | -3.7x | -5.0x | 2.0x | 2.0x |
R&D budget | 3.5m | 5.1m | 3.1m | 2.4m | 2.6m | 3.2m | 2.8m |
R&D % of revenue | 20 % | 32 % | 33 % | 32 % | 31 % | 39 % | 47 % |
Date | Investors | Amount | Round |
---|---|---|---|
$14.0m | Series D | ||
N/A | N/A | IPO | |
N/A | $18.7m | Post IPO Equity | |
N/A | $14.7m | Post IPO Equity | |
N/A | $13.8m | Post IPO Equity | |
N/A | $21.0m | Post IPO Equity | |
N/A | $7.0m | Post IPO Equity | |
N/A | $3.5m | Post IPO Equity | |
Total Funding | CAD19.1m |
Related Content
Recent News about NeuroMetrix
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by NeuroMetrix
EditACQUISITION by NeuroMetrix Dec 2007